<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00612976</url>
  </required_header>
  <id_info>
    <org_study_id>1312006001</org_study_id>
    <secondary_id>budesonide /formoterol</secondary_id>
    <secondary_id>German PMS trial no.8</secondary_id>
    <nct_id>NCT00612976</nct_id>
  </id_info>
  <brief_title>Symbicort in Chronic Obstruktive Pulmonary Disease</brief_title>
  <acronym>SYMBIOSE</acronym>
  <official_title>Symbicort in Chronic Obstruktive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Under daily routine conditions and without any intervention by the sponsor regarding the
      selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non-
      medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians
      (i.e.general practitioners and internists) are asked to document relevant data related to the
      budesonide/formoterole therapy in patients with COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy and tolerability of budesonide /formoterole in subjects with COPD who are treated by general practitioners and internists.</measure>
    <time_frame>change of a quality of life score compared to baseline by using CRQ, stratified by present therapy and severity of COPD; incidence of the occurrence of unknown, unexpected and/or rarely occurring adverse events AE under outpatient medical care conditions</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>to get further insight into the details of the use , dosage scheme and duration of treatment with budesonide /formoterol in this population</measure>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">18014</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients with COPD treated with budesonide/formoterol</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        general practitioners and internists
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with COPD treated with budesonide/formoterol

        Exclusion Criteria:

          -  limitiations; possible risks; warnings; contraindications mentioned in the SPC.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai Richter, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical Department AstraZeneca Germany</affiliation>
  </overall_official>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2008</study_first_submitted>
  <study_first_submitted_qc>February 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2008</study_first_posted>
  <last_update_submitted>February 11, 2008</last_update_submitted>
  <last_update_submitted_qc>February 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr Kai Richter</name_title>
    <organization>AstraZeneca Germany</organization>
  </responsible_party>
  <keyword>treatment of COPD</keyword>
  <keyword>documentation of relevant data</keyword>
  <keyword>related to the budesonide/formoterole therapy in patients with COPD.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

